Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Diffuse Large B-Cell Lymphoma Refractory 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × loncastuximab tesirine × Clear all
NCT05144009 2025-01-30

LOTIS-9

ADC Therapeutics S.A.

Phase 2 Terminated
41 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04699461 2023-10-23

LOTIS-6

ADC Therapeutics S.A.

Phase 2 Terminated
6 enrolled 9 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03589469 2023-08-29

LOTIS-2

ADC Therapeutics S.A.

Phase 2 Completed
145 enrolled 24 charts 1 FDA
Lymphoid

Diffuse Large B-Cell Lymphoma Refractory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡